IMPORTANT advice from expert bodies about basic management of diabetes and the investigation of kidney disease which will inform the everyday care of patients is featured in the latest MJA.
Associate Professor Wah Cheung, the President of the Australian Diabetes Society, encourages us to individualise both the glycated haemoglobin (HbA1c) targets that we strive for in our patients and the choice of pharmacotherapy used.
There are now so many medicines for treating type 2 diabetes that it is difficult to know what is most appropriate. It is reassuring to read that an old but a good one, metformin, is still high on the treatment pyramid.
After many years of discussion and dissent, HbA1c has finally earned its place as a tool in the diagnosis of diabetes. Although there are important exceptions, an HbA1c level greater than 6.5% is now regarded as diagnostic for diabetes.
This test can be done at any time of day without preparation and, unlike serum glucose, is stable if the blood sample is appropriately collected.
Considering that about half of Australians over the age of 25 years with type 2 diabetes remain undiagnosed, and the incontrovertible evidence that effective management reduces complications, a simple diagnostic test is long overdue. It seems appropriate that Medicare now fund this test for this purpose.
The curly question of redefining gestational diabetes and the challenges this brings are discussed in this issue. The trade-off of possible benefit from intervention at lower blood glucose levels needs to be balanced against the risks of over-medicalisation and diversion of resources away from those most in need.
The concern of how our medical system will cope has already been aired in the Journal (MJA 2011; 194: 338-340, MJA 2011; 195: 268).
For too long, diabetes-related foot disease (DRFD) has been inadequately addressed in our health system. In an editorial, members of the Australian Diabetes Foot Network remind us that one Australian loses a lower limb every 3 hours as a direct result of DRFD and that this has increased by almost a third over the past decade. They convincingly argue that our health system does not fund evidence-based care that includes basic measures such as wound dressings, total contact casting, walking braces, and suitable footwear and orthotics.
In no group is this more apparent than Indigenous Australians with diabetes, who are 38 times more likely to undergo a major leg amputation than non-Indigenous Australians with diabetes.
The authors provide valuable management guidance for DRFD that includes sensible and readily available care such as daily cleaning with saline or water instead of surface antiseptics.
A letter outlines a troubling finding that the incidence of diabetic ketoacidosis in young people remains high. The authors encourage education to improve early recognition and diagnosis of diabetes and, hopefully, prevention of this serious complication.
If the kidneys have always presented a bit of a challenge, you may welcome the sensible and simple guidance regarding the assessment of renal function. The authors say, “Optimal detection and subsequent risk stratification of people with chronic kidney disease requires simultaneous consideration of both kidney function … and kidney damage (as indicated by albuminuria or proteinuria)”.
Clearly we know a lot about managing diabetes and its complications, although simple measures that could improve care and prevent suffering, including diet and exercise, are not always put into practice.
Diabetes is Australia’s fastest growing chronic condition, with a reported 275 people diagnosed every day.
As we get back to basics with management, we need to ponder the larger question of how to stem this alarming tide.
Maybe the solutions are simpler than we think.
This article is reproduced from the MJA with permission.
Posted 20 August 2012
It would be hard to think of a condition for the phrase which “prevention is better than cure” is more apt than for type II diabetes.
We know that it is related to the metabolic syndrome, the primary pathology of which is abdominal obesity. See: Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep. 2008 Apr;10(2):156-64.
Abdominal obesity has become epidemic over the past 30 years and is associated with mass marketing of high fat, high sugar high salt so-called “hyperpalatable” foods.
See: Cizza G, Rother KI. Beyond fast food and slow motion: weighty contributors to the obesity epidemic. J Endocrinol Invest. 2012 Feb; 35(2):236-42.
Anderson B, Rafferty AP, Lyon-Callo S, Fussman C, Imes G. Fast-food consumption and obesity among Michigan adults. Prev Chronic Dis. 2011 Jul;8(4):A71.
Clearly some form of increased regulation is needed here as current methods are not working.